v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Revenues
Cost and expenses:    
Research and development 22,235 2,539,568
General and administrative 1,258,360 2,642,749
Total operating expenses 1,280,595 5,182,317
Loss from operations (1,280,595) (5,182,317)
Other income (expense):    
Interest expense, net (24,811) (4,349)
Change in fair value of contingent consideration and derivative financial instruments (4,800,481) 1,930,652
Inducement expense (2,567,044)
Loss before income taxes (6,105,887) (5,823,058)
Income tax benefit 2,969,252
Net loss $ (6,105,887) $ (2,853,806)
Weighted-average common shares outstanding:    
Weighted-average common shares outstanding basic 2,836,700 101,450
Weighted-average common shares outstanding diluted 2,836,700 101,450
Net loss per common share: (see Note 10)    
Net loss per common share basic $ (2.15) $ (28.13)
Net loss per common share diluted $ (2.15) $ (28.13)